VEGF-binding KDR polypeptide

The present invention relates to polypeptides which are useful as neovascularization inhibitors, and a method of producing them. A novel polypeptide is provided, which can be utilized to treat diseases accompanying neovascularization, such as solid tumors, and is useful as a low molecular weight VEGF inhibitor. The polypeptide contains immunoglobulin-like domain 1 and immunoglobulin-like domain 2 of the extracellular domain of the VEGF receptor KDR. Since it has smaller molecular weight than the conventional polypeptides with retaining VEGF inhibitory activity, it is expected that it can be readily expressed using recombinant DNA techniques and infiltrates into diseased sites more quickly.